Single-chamber prefilled syringes market seen reaching $25.79 billion by 2030

The global single-chamber prefilled syringes market is projected to grow from $11.97 billion in 2025 to $25.79 billion by 2030, driven by rising demand for safer, more precise injectable drug delivery. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Single-chamber prefilled syringes are gaining traction because they can improve dosing accuracy and reduce medication errors in clinical and home-care settings. - Rising demand for injectable therapies, including biologics and self-administered drugs, is supporting long-term market expansion. - The growth outlook matters for drug makers, packaging suppliers and healthcare providers focused on safer and more convenient delivery systems.

What happened: - The Business Research Company projected the single-chamber prefilled syringes market will rise from $11.97 billion in 2025 to $13.93 billion in 2026. - The market is forecast to reach $25.79 billion by 2030, implying a 16.7% compound annual growth rate. - The report is titled The Business Research Company's Single-Chamber Prefilled Syringes Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The company published the report from London on Aug. 26, 2026. - Download a free sample of the market report. - View the full market report.

The details: - Single-chamber prefilled syringes are preloaded with a set dose of medication in one compartment. - The format is designed to simplify drug administration and help ensure accurate dosing. - The market's historic growth has been driven by more injectable drug formulations, expanded vaccination programs, growth in biologics production, stricter patient safety standards and advanced packaging materials. - Forecast growth is expected to come from more self-administered injectables, a larger biologics pipeline, increased home-based drug administration, demand for sustainable packaging and adoption in emerging economies. - The report flags broader use of prefilled injection systems, preference for ready-to-use injectable formats, more plastic syringe components, expanded vaccine and biologic packaging uses and a stronger focus on dose precision and patient safety. - Chronic diseases such as diabetes and cancer are adding to demand because injectable therapies often require reliable, accurate delivery. - The World Health Organization said in February 2024 that new cancer cases could exceed 35 million by 2050, up 77% from about 20 million in 2022. - North America held the largest share of the global market in 2025. - Asia-Pacific is projected to be the fastest-growing region in the coming years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast points to a broader shift toward ready-to-use drug delivery formats that can support both efficiency and patient safety. - The emphasis on biologics, home care and self-administration suggests demand is moving beyond hospitals into everyday treatment settings. - The regional outlook indicates mature markets will keep volume, while faster growth may come from healthcare investment and biologics manufacturing in Asia-Pacific.

What's next: - The report says future market momentum will likely depend on uptake of prefilled systems, packaging innovation and expansion in emerging markets. - The Business Research Company also highlighted new report features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics and updated graphics and tables. - The company listed Saumya Sahay as a contact for expert inquiries, with phone and email details provided in the release. - The Business Research Company also directed readers to its LinkedIn, Facebook and X accounts.